Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.96 per share, representing an earnings surprise of -4.17% [1] - The company posted revenues of $186.52 million for the quarter, which also fell short of the Zacks Consensus Estimate by 1.08% [2] Financial Performance - Earnings per share (EPS) for the same quarter last year was $0.88, indicating a year-over-year increase [1] - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - Revenue for the previous year was $178.11 million, showing growth in revenue year-over-year [2] Market Performance - Amphastar shares have declined approximately 15.9% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current Zacks Rank for Amphastar is 4 (Sell), indicating expected underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $176.16 million, while the estimate for the current fiscal year is $3.50 on revenues of $746.67 million [7] - The trend of estimate revisions for Amphastar is currently unfavorable, which could impact future stock performance [6] Industry Context - The Medical - Generic Drugs industry is ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8]